StockNews.AI
BBIO
StockNews.AI
3 days

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

1. BBIO to present Phase 2 data at ASBMR Annual Meeting. 2. Key presentations on post-surgical hypoparathyroidism and skeletal dysplasia scheduled. 3. Oral and poster sessions focus on new treatment efficiencies. 4. Presentations may strengthen BBIO's market position in genetic diseases. 5. Data could attract investor and clinical interest in BBIO.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive data presentations can enhance investor confidence. Similar past events have led to stock price increases.

How important is it?

Presentations at major conferences can significantly impact investor sentiment and stock valuation.

Why Short Term?

Upcoming presentations are immediate catalysts for price movement, usually within weeks.

Related Companies

VRTXREGNAMGN
September 02, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025. Post-Surgical Hypoparathyroidism Oral Presentation:The Oral Calcilytic Encaleret Reduced Urinary Calcium While Maintaining Blood Calcium in Individuals with Post-Surgical HypoparathyroidismPresenter: Iris Hartley, M.D., National Institute of Dental and Craniofacial Research, National Institutes of HealthDate/time: Saturday, September 6 at 11:30 am PT Skeletal Dysplasia Poster Sessions:Infigratinib Low Dose Therapy Is an Effective Strategy in Improving Bone Growth in a Hypochondroplasia Mouse Model Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBioDate/time: Friday, September 5 at 5:00 pm PT and Sunday, September 7 at 2:00 pm PT Infigratinib Improves Skull Measures in a Mouse Model of Crouzon/Pfeiffer SyndromesPresenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBioDate/time: Saturday, September 6 at 2:00 pm PT About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube. BridgeBio Media Contact: Bubba Murarka, Executive Vice President, Corporate Development contact@bridgebio.com   (650)-789-8220 BridgeBio Investor Contact: Chinmay Shukla, Senior Vice President, Strategic Financeir@bridgebio.com  

Related News